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Rapamycin has been reported to enhance tissue factor (TF) expression. The present study investi-
gated roles of mammalian target of rapamycin (mTOR) and its downstream S6K1 in this process.
We showed here that, consistent with rapamycin, knocking-down mTOR enhanced thrombin-
induced TF mRNA and protein levels, whereas silencing S6K1 mitigated up-regulation of TF protein
but not TF mRNA level. The enhanced TF protein level upon mTOR-silencing was further augmented
by over-expression of a constitutively active S6K1 mutant and reduced by blocking RhoA, p38mapk or
NF-jB. The results reveal an opposing and uncoupling effect of mTOR and S6K1 in regulating TF
expression.
1. Introduction
Tissue factor (TF), the key enzyme in extrinsic coagulation cas-
cade, triggers the coagulation leading to local formation of throm-
bin at vascular injury sites [1]. In a positive feedback mechanism,
thrombin up-regulates vascular TF expression [2,3], that plays a
crucial role in acute thrombotic episodes [1]. Endothelial TF
expression is up-regulated by multiple signaling pathways includ-
ing RhoA, p38mapk, p44/42ERK, JNK, and NF-jB [2–4]. In contrast,
PI3-K reduces endothelial TF expression independently of its
downstream effectors Akt/eNOS [3]. Numerous studies including
our own showed that rapamycin enhances endothelial TF expres-
sion, suggesting that mammalian target of rapamycin (mTOR) sup-
presses endothelial TF expression [5–7]. These ﬁndings raise some
concern about the prothrombotic risk of rapamycin (sirolimus)-
eluting stents in patients with coronary artery disease [8]. Despite
the well documented effect of rapamycin on TF expression, it re-
mains elusive whether the rapamycin’s effect is indeed attributed
to mTOR and through its downstream effector S6K1 [5–7].
S6K1 phosphorylates the 40S ribosomal protein S6, resulting in
enhanced protein translation [9]. Activation of S6K1 relies on the
direct phosphorylation of Thr389 and Thr229 by mTOR and
PDK1, respectively [10,11]. mTOR–S6K1 pathway is involved in
various cellular functions e.g. cell growth, differentiation, and
motility [9]. Although many effects of mTOR are consistent with
those of S6K1 [12], there is evidence showing that not all the func-
tions of mTOR are mediated through S6K1. For example, mouse
myocyte proliferation is blunted by inhibition of mTOR, but not af-
fected by S6K1 deletion [13].
In the present study, we investigated roles of mTOR and S6K1 in
endothelial TF expression by recombinant adenovirus (rAd)-based
interfering RNA (RNAi) approach.
2. Materials and methods
2.1. Materials
See the Supplementary data.
2.2. Generation of rAds
Generation of rAd expressing short hairpin RNA (shRNA)
targeting human mTOR or S6K1 driven by the U6 promoter (rAd/
U6-mTORshRNA or -S6K1shRNA, respectively) was carried out as
Abbreviations:mTOR, mammalian target of rapamycin; TF, tissue factor; HUVEC,
human umbilical vein endothelial cell; rAd, recombinant adenovirus; shRNA, short
hairpin RNA
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described previously [14]. The control rAd/U6-LacZshRNA was from
Invitrogen. The mTOR and S6K1 targeting sequences are
CCGCATTGTCTCTATCAAGTT and GGACATGGCAGGAGTGTTTGA,
respectively. rAd/CMV-HA-Rho19 (a dominant negative mutant
of RhoA) was described previously [15]. rAd/CMV-HA-S6K1-ca (a
constitutively active S6K1 mutant F5A-E389-R3A) [16] and -HA-
IjBa-AA (the super-repressor IjBa) [17] was kindly provided by
Dr. S. Huang (Louisiana State University, USA) and Dr. S. Giovanni
(University of Fribourg, Switzerland), respectively.
2.3. Cultivation and adenoviral transduction of human umbilical vein
endothelial cells (HUVECs)
Cultivation and transduction of HUVECs were performed as pre-
viously described [15]. For all experiments, cells were stimulated
with thrombin (4 U/mL) or TNFa (10 ng/mL) at day 4 of post-trans-
duction after overnight serum-starvation in 0.2% FCS-RPMI. Cells
were treated for 4 h or indicated time for TF expression or signaling
activation, respectively.
2.4. Activation of mTOR, S6K1, p38mapk, and NF-jB pathway
Activation of mTOR, S6K1 or p38mapk was assessed by monitor-
ing phosphorylation of S6K1-Thr389, S6-Ser235/236 or p38mapk –
Thr180/Tyr185, respectively. Activation of NF-jB pathway was
analysed by IjBa phosphorylation and degradation by immuno-
blotting. Cell lysate preparation, immunoblotting and quantiﬁca-
tion of the signals were performed as previously described [14].
2.5. RhoA activation
The RhoA activation was assessed by the pull-down assay as
previously described [15].
Fig. 1. Time course of mammalian target of rapamycin (mTOR)-S6K1 activation by
thrombin. Human umbilical vein endothelial cells (HUVECs) were stimulated with
thrombin for the indicated time after overnight serum-starvation. Cell lysates were
subjected to immunoblotting analysis of S6K1- and S6-phosphorylation to assess
mTOR and S6K1 activation, respectively. Shown is one of three independent
experiments.
Fig. 2. Effects of silencing S6K1 and mTOR on thrombin-induced tissue factor (TF)
mRNA expression. (A) Immunoblotting analysis of (a) mTOR expression; (b) S6K1
expression with mobility shift; (c) mTOR-mediated phosphorylation of S6K1-
Thr389; (d) S6K1-mediated phosphorylation of S6-Ser235/236 and (e) tubulin in
LacZshRNA-, S6K1shRNA- or mTORshRNA-expressing cells. Shown are representative
blots from three independent experiments. (B) TF mRNA expression by real-time
qRT-PCR. Data from three independent experiments are reported as mean ± S.E.M.
Fig. 3. Silencing S6K1 abrogated thrombin-induced TF protein level and TF activity.
Cells were treated as in Fig. 2 and TF protein level was examined by (A)
immunoblotting. (B) Quantiﬁcation of TF/tubulin signals from ﬁve independent











2.6. TF activity assay
After treatment, cells were extracted using 50 mmol/L Tris-buf-
fered saline (pH 8.0) with 1% Triton-X-100 and centrifuged at
14 000g for 20 min. The supernatant containing same amount
of protein was subjected to TF activity measurement using a chro-
mogenic activity assay kit (AssayPro, #CT1002b) according to man-
ufacturer’s instruction.
2.7. Quantitative real-time reverse transcription PCR (qRT-PCR)
TF mRNA expression was evaluated by two-step qRT-PCR. Total
RNA was extracted with SV total RNA isolation system (Promega).
First-stranded cDNA was synthesized from 500 ng total RNA with a
random primer. Real-time PCR was performed with the iQTM SYBR
Green Supermix and iCycler system (Bio-Rad). TF mRNA expres-
sions were normalized to the reference gene glyceraldehyde 3-
phosphate dehydrogenase (GAPDH).
2.8. Statistical analysis
The effects of S6K1shRNA, mTORshRNA or other treatments were
calculated as % relative to thrombin-induced TF expression/activity
in LacZshRNA-control cells which served as 100%. All data were gi-
ven as mean ± S.E.M. The ANOVA with Bonferroni post hoc test
was used for statistical analysis. A two-tailed value of P < 0.05
was considered as statistically signiﬁcant difference. ***P < 0.001,
**P < 0.01, *P < 0.05 between the indicated groups.
3. Results
3.1. Thrombin activates mTOR and S6K1 in endothelial cells
Activation of mTOR as monitored by phosphorylation of S6K1 at
Thr389 was observed at 5–15 min upon thrombin stimulation in
HUVECs (Fig. 1A), while activation of S6K1 i.e. phosphorylation of
S6 at Ser235/236 was detectable at 15–30 min (Fig. 1B).
3.2. Silencing mTOR, but not S6K1, enhances thrombin-induced TF
mRNA expression
Knock-down of mTOR or S6K1 reduced their expression
(Fig. 2Aa or Ab, lanes 5 and 6 or lanes 3 and 4, respectively) and
phosphorylation of their substrates (Fig. 2Ac or Ad, lane 6 or 4
compared with lane 2) in parallel. Of note, there was a basal phos-
phorylation of S6K1 and S6 (Fig. 2Ac and Ad, lane 1), and the acti-
vation of mTOR–S6K1 pathway could also be appreciated by the
mobility shift of S6K1 upon thrombin stimulation (Fig. 2Ab, lane
2). Thrombin-induced TF mRNA expression was not signiﬁcantly
affected by silencing S6K1, but remarkably enhanced by knock-
ing-down mTOR when compared with LacZshRNA-control cells
(Fig. 2B, n = 3; P < 0.001 vs. LacZshRNA).
3.3. Opposing and uncoupling effects of mTOR and S6K1 on TF protein
level and activity
Interestingly, the thrombin-enhanced TF protein level (Fig. 3A
and B, lane 2) was prevented by silencing S6K1 (Fig. 3A and B,
lane 4; n = 5, P < 0.001 vs. lane 2), but signiﬁcantly enhanced
by knocking-down mTOR (Fig. 3A and B, lane 6; n = 5, P < 0.05
Fig. 4. Over-expression of a constitutively active S6K1 (S6K1-ca) augmented
thrombin-induced TF protein level. Cells were ﬁrst transduced with recombinant
adenovirus (rAd)/U6-LacZshRNA or rAd/U6-mTORshRNA for 3 days followed by trans-
duction with rAd/CMV-LacZ or rAd/CMV-HA-S6K1-ca for 1 day before treatment
with thrombin. (A) Immunoblotting analysis of expression of HA-S6K1-ca with anti-
HA antibody, S6-Ser235/236, TF and tubulin. (B) Quantiﬁcation of TF/tubulin signals
from three independent experiments.
Fig. 5. Effects of inhibition of S6K1-independent pathways on TF protein level. Cells
expressing LacZshRNA (lanes 1–6) or mTORshRNA (lanes 7–12) were pre-treated with
various signaling inhibitors as indicated for 1 h before stimulation with thrombin:
10 lmol/L ﬂuvastatin (FS), 10 lmol/L MG-132 (MG), 50 lmol/L PD98059 (PD),
10 lmol/L SB202190 (SB). Same amount of solvent was added to the control cells.
(A) Immunoblotting analysis of TF and tubulin expression. (B) Quantiﬁcation of the











vs. lane 2). The effects of silencing mTOR or S6K1 on TF protein
levels were well correlated with those on cellular TF activity
(Fig. 3C, n = 3). Moreover, over-expression of a HA-tagged consti-
tutively active S6K1 (HA-S6K1-ca) in LacZshRNA-control cells
(Fig. 4Aa, lanes 3 and 4) augmented thrombin’s effect on TF pro-
tein level (Fig. 4Ac and B, lane 4 vs. lane 2, P < 0.05). Of note,
over-expression of HA-S6K1-ca alone (panel a, lane 3), despite
the enhanced S6K1-mediated S6-phosphorylation (panel b, lane
3), was not sufﬁcient to signiﬁcantly increase TF protein level
(Figs. 3Ac and 4B, lane 3). Under the condition of mTOR-silenc-
ing, whereby thrombin-induced up-regulation of TF protein level
was augmented as compared with the control cells (Fig. 4Ac and
B, lane 6 vs. lane 2), over-expression of HA-S6K1-ca further in-
creased TF protein to the highest level (Fig. 4Ac and B, lane 8),
reinforcing that mTOR and S6K1 exerts opposing and uncoupling
effects on endothelial TF expression at mRNA and protein trans-
lational level, respectively. The requirement of S6K1 for TF pro-
tein up-regulation was further conﬁrmed with TNFa. Like
thrombin, TNFa activated S6K1 (Supplementary Fig. 1Ab, lane
2) and enhanced TF protein level (Supplementary Fig. 1Ac and
B, lane 2 vs. lane 1) in LacZshRNA-control cells, which was re-
duced by silencing S6K1 (Supplementary Fig. 1Ac and B, lane 4
vs. lane 2).
3.4. Roles of mTOR–S6K1-independent signalings in TF up-regulation
Inhibition of RhoA, NF-jB, or p38mapk with ﬂuvastatin, MG-132,
or SB202190, respectively, blunted thrombin-induced TF protein
level in LacZshRNA-control cells, whereas blockade of p42/p44mapk
with PD98059 had no effect (Fig. 5, shaded bars, lanes 1–6). The
augmented thrombin-induced TF protein level after knocking-
down mTOR (lane 8 vs. lane 2) was also signiﬁcantly reduced by
ﬂuvastatin, MG-132, or SB202190, but not by PD98059 (Fig. 5, gray
bars, lanes 7–12). Similar results were obtained with over-expres-
sion of a dominant negative mutant of RhoA (Rho19) or the super-
repressor IjBa (IjBa-AA) (Fig. 6).
Fig. 6. Over-expression of dominant negative mutant of RhoA (Rho19) or super-repressor IjBa (IjBa-AA) blunted thrombin-induced TF protein level. (A) Immunoblotting
analysis of expression of TF, tubulin, and HA-tagged transgenes with anti-HA antibody in cells transduced ﬁrst with U6/LacZshRNA or U6/mTORshRNA followed by transduction











3.5. mTOR and S6K1 do not interfere with activation of RhoA, NF-jB or
p38mapk
Stimulation of the cells with thrombin for indicated time acti-
vated RhoA, NF-jB, and p38mapk pathways (Supplementary Fig. 2,
lane 2, n = 3). These effects of thrombin were however, not affected
by silencing of either S6K1 or mTOR (lane 4 or 6, respectively,
n = 3). Of note, despite induction of IjBa phosphorylation, throm-
bin did not cause signiﬁcant degradation of IjBa in the cells.
4. Discussion
Numerous studies including our own reported the inhibitory ef-
fect of mTOR on TF expression based on the observation that rap-
amycin enhances TF expression in vascular cells [5–7]. In the
present study, we demonstrate that silencing mTOR, in agreement
with rapamycin, also markedly enhanced thrombin-induced TF
mRNA (Fig. 2). In contrast, silencing S6K1 reduced thrombin-in-
duced TF protein level without affecting TF mRNA expression (Figs.
2 and 3A and B). The opposing effects of silencing mTOR and S6K1
on TF protein level (Fig. 3A and B) were also reﬂected by their
opposing effects on the cellular TF activity (Fig. 3C). Moreover,
TNFa-induced TF protein level was also inhibited by silencing
S6K1 (Supplementary Fig. 1). These results demonstrate that
S6K1 does not mediate mTOR’s suppressing effect on TF mRNA
expression but instead enhances TF protein translation. The posi-
tive regulatory effect of S6K1 on TF protein level was further con-
ﬁrmed by over-expression of a constitutively active S6K1 mutant
which enhances thrombin’s effect on TF protein level in both
LacZshRNA-control and mTOR-silenced cells (Fig. 4). It is noteworthy
that the enhanced TF protein level after mTOR-silencing was fur-
ther augmented by expression of the active S6K1 mutant (Fig. 4).
These results provide further convincing evidence for the opposing
and uncoupling effect of mTOR and S6K1 in endothelial TF expres-
sion, and imply that the much weaker enhancement in TF protein
level vs. TF mRNA after knocking-down mTOR (Fig. 3 vs. Fig. 2)
could be explained by the concomitant inhibition of S6K1.
The fact that knocking-down mTOR enhances TF protein level
despite concomitant inhibition of S6K1-mediated TF protein trans-
lation, suggest that other mTOR–S6K1-independent signalings
must exist. Indeed, blockade of RhoA, NF-jB, and p38mapk, but
not p44/42ERK by pharmacological inhibitors and/or by over-
expression of dominant negative mutants reduced up-regulation
of TF protein level upon thrombin stimulation or mTOR-silencing
(Figs. 5 and 6), demonstrating that mTOR and S6K1 in concert with
those signalings regulate endothelial TF expression in a complex
manner as depicted in the Fig. 7. It seems that silencing mTOR or
S6K1 does not affect activation of these pathways in response to
thrombin, since phosphorylation levels of the protein kinases or
formation of RhoA-GTP were not affected under these conditions
(Supplementary Fig. 2). The results suggest that the markedly en-
hanced TF mRNA expression upon mTOR-silencing is likely trans-
lated by these S6K1-independent pathways (Fig. 7). It is to point
out that interactions between mTOR–S6K1 and these pathways
at more downstream levels cannot be excluded.
In summary, this study demonstrates an opposing and uncou-
pling effect of mTOR and S6K1 in regulation of endothelial TF
expression. While mTOR suppresses endothelial TF mRNA expres-
sion, S6K1 is required for TF protein translation, which works in
concert with other signaling pathways such as RhoA, p38mapk,
and NF-jB (Fig. 7). Our ﬁndings may have potential clinical impli-
cations. Some clinical studies reported that rapamycin (sirolimus)-
eluting stents, despite its property of preventing vascular resteno-
sis in patients with coronary artery disease, may have increased
thrombotic risk [8], which might be partly related to the increased
TF expression/activity through inhibition of mTOR in the vascular
cells. It would be interesting to test whether inhibition of S6K1
alone, rather than mTOR as achieved by rapamycin, proves sufﬁ-
cient to prevent vascular restenosis and be superior in reducing
thrombotic propensity by developing speciﬁc S6K1 inhibitors.
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